In AD-converters who are initially cognitively unimpaired, we find that higher plasma GFAP levels are observed as early as 10-years prior to the onset of cognitive impairment due to incident AD compared to those who remain cognitively unimpaired (i.e. in CU). The gene discussed is GFAP; the disease is Alzheimer disease.